Business
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced its participation at the SCOPE Summit 2026, the 17th annual conference organized by the Cambridge Healthtech Institute. SCOPE (Summit for Clinical Ops Executi
About this update from Oragenics Inc.
[{"type":"image","alt":"Oragenics, Inc.","displaySize":"","headline":null,"caption":"Oragenics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/02a218ac180e2bd4098942c8c71e4535"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EJO5t_9yeEA4D97YiOoXog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/02a218ac180e2bd4098942c8c71e4535","width":300,"height":114}},"lazy":false},{"type":"text","content":"Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment","length":106,"tagName":"p"},{"type":"text","content":"Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced its participation at the SCOPE Summit 2026, the 17th annual conference organized by the Cambridge Healthtech Institute. SCOPE (Summit for Clinical Ops Executives) is a clinical research conference being held February 2–5, 2026, in Orlando, Florida.","length":483,"tagName":"p"},{"type":"text","content":"“Oragenics is excited to participate in one of the premier global conferences for clinical operations and optimal trial execution — a timely event as we approach the Phase 2a clinical trial of our first-of-its-kind concussion therapeutic in Australia,” said Janet Huffman, Chief Executive Officer. “We look forward to engaging with experts from biopharma, scientific research, and regulatory affairs at SCOPE, especially the technology innovators advancing medical progress and bolstering the body of scientific knowledge.”","length":523,"tagName":"p"},{"type":"text","content":"Oragenics is working towards advancing neurological care through its proprietary intranasal delivery platform designed to enable targeted, non-invasive delivery of therapeutics directly to the brain. Its lead candidate, ONP-002, is advancing toward Phase 2a clinical trials in Australia with the goal of developing it as a treatment for concussion and mild traumatic brain injury—conditions with significant unmet medical need and no FDA-approved therapies.","length":457,"tagName":"p"},{"type":"text","content":"The SCOPE Summit welcomes senior executives from p...